{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=49&state=Pennsylvania",
    "query": {
      "state": "Pennsylvania",
      "city": "Philadelphia",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 17147,
    "total_pages": 1715,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=50&state=Pennsylvania&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=48&state=Pennsylvania&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T14:59:41.931Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06826859",
      "title": "Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Preterm Birth",
        "Preeclampsia"
      ],
      "interventions": [
        {
          "name": "Daily aspirin (ASA)",
          "type": "DRUG"
        },
        {
          "name": "Split dose aspirin (ASA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 55 Years · Female only"
      },
      "enrollment_count": 400,
      "start_date": "2025-06-26",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06826859"
    },
    {
      "nct_id": "NCT00902759",
      "title": "Fatigue and Pancreas and Bile Duct Cancer Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Walking Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2009-01-09",
      "completion_date": "2015-04-15",
      "has_results": false,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00902759"
    },
    {
      "nct_id": "NCT02797080",
      "title": "Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "interferon γ-1b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "27 Years",
        "sex": "ALL",
        "summary": "11 Years to 27 Years"
      },
      "enrollment_count": 38,
      "start_date": "2016-06-28",
      "completion_date": "2017-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02797080"
    },
    {
      "nct_id": "NCT01705496",
      "title": "[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prosthetic Joint Infections"
      ],
      "interventions": [
        {
          "name": "[124I]FIAU",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "BioMed Valley Discoveries, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2012-08",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2016-03-07",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 10,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 7 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01705496"
    },
    {
      "nct_id": "NCT01696396",
      "title": "Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Abrilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 254,
      "start_date": "2012-12-04",
      "completion_date": "2018-04-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-27",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696396"
    },
    {
      "nct_id": "NCT02536196",
      "title": "The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Symptomatic Aortic Stenosis"
      ],
      "interventions": [
        {
          "name": "Embolic Protection Device",
          "type": "DEVICE"
        },
        {
          "name": "Transcatheter aortic valve implantation (TAVI)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Keystone Heart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 478,
      "start_date": "2016-06",
      "completion_date": "2019-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • San Diego, California • New Haven, Connecticut + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02536196"
    },
    {
      "nct_id": "NCT00387088",
      "title": "Tiotropium / Respimat One Year Study in COPD.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Respimat",
          "type": "DEVICE"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 3991,
      "start_date": "2006-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-16",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Berkeley, California + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00387088"
    },
    {
      "nct_id": "NCT03561103",
      "title": "Impact of Representative Payee Services on ART Adherence Among Marginalized People Living With HIV/AIDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Client-Centered Representative Payee",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 91,
      "start_date": "2017-05-01",
      "completion_date": "2024-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03561103"
    },
    {
      "nct_id": "NCT00101127",
      "title": "Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2003-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-02-14",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 60,
      "location_summary": "Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 47 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101127"
    },
    {
      "nct_id": "NCT01440088",
      "title": "A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "TH-302 in Combination with Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Threshold Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 640,
      "start_date": "2011-09",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-02",
      "last_synced_at": "2026-11-19T14:59:41.931Z",
      "location_count": 44,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 35 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01440088"
    }
  ]
}